A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT05741021 · UNKNOWN
Trial details
- NCT number
- NCT05741021
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-01
- Primary completion
- 2024-10-25
- Enrollment
- 84
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.